26 February 2021
Successful completion of £25 million Fundraise
Shield Therapeutics plc, is pleased to announce the successful completion of the placing (the “Placing“), and the subscription (the “Subscription”) which were announced earlier today raising aggregate gross proceeds of up to £25.0 million for the Company (approximately £23.6 million net of expenses). The new ordinary shares to be allotted pursuant to the Placing and the Subscription are to be issued at an issue price of 30.0 pence per share (the “Issue Price”). The Company also announced details of an open offer to be made to Qualifying Shareholders to raise up to an additional £4.2 million (the “Open Offer”, and together with the Placing and the Subscription, the “Transaction”). For further details click here.